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Summary
Background.  —  The  optimal  therapy  for  in-stent  restenosis  (ISR)  is  controversial.  We  evaluated
three different  strategies  for  the  treatment  of  in-stent  restenosis:  cutting  balloon  angioplasty
(CBA), paclitaxel-eluting  balloon  angioplasty  (PEBA)  and  cutting  balloon  followed  by  paclitaxel-
eluting balloon  angioplasty  (CB  +  PEBA).
Methods.  —  Forty-ﬁve  coronary  arteries  in  45  mini-pigs  underwent  oversized  bare-metal  stent
(stent-to-artery  ratio,  1.2:1)  implantation  to  induce  in-stent  restenosis.  After  28  days,  vessels
with in-stent  restenosis  (≥  50%  diameter  stenosis)  were  randomly  divided  into  three  groups:
CBA, PEBA  and  CB  +  PEBA.  In  vivo  angiography  was  performed  before  intervention,  immediately
after intervention  and  at  28-day  follow-up.  Stented  arteries  were  harvested  for  pathological
Abbreviations: AS%, percentage of lumen area stenosis; BMS, bare-metal stent; CBA, cutting balloon angioplasty; CB+PEBA, cutting
balloon followed by paclitaxel-eluting balloon angioplasty; EELA, elastic lamina area; IELA, internal elastic lamina area; ISR, in-stent
restenosis; LA, lumen area; LD, lumen diameter; NA, neointimal area; PCNA, proliferating cell nuclear antigen; PEBA, paclitaxel-eluting
balloon angioplasty; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labelling; VSMCs, vascular smooth muscle cells.
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analyses.  The  proliferation  and  apoptosis  of  vascular  smooth  muscle  cells  were  evaluated  by
immunohistochemical  staining  and  the  terminal  deoxynucleotidyl  transferase  dUTP  nick  end
labelling (TUNEL)  assay,  respectively.
Results.  —  Acute  lumen  gain  was  not  different  between  the  three  groups.  Late  lumen  loss
and neointimal  area  at  follow-up  were  lower  for  CB  +  PEBA  compared  with  CBA  but  similar
for CB  +  PEBA  compared  with  PEBA.  There  were  no  signiﬁcant  differences  in  proliferating  cell
nuclear antigen-positive  vascular  smooth  muscle  cells  and  TUNEL-positive  vascular  smooth
muscle cells  between  the  CB  +  PEBA  and  PEBA  groups.
Conclusions.  —  PEBA  with  or  without  cutting  balloon  was  superior  to  CBA  alone  for  in-stent
restenosis.  The  underlying  mechanism  was  probably  related  to  inhibition  of  smooth  muscle  cell
proliferation  and  increased  apoptosis.  In  this  porcine  coronary  artery  restenosis  model,  PEBA
with or  without  cutting  balloon  was  superior.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Justiﬁcation.  —  Le  traitement  optimal  de  la  resténose  intra-stent  reste  controversé.  Nous  avons
évalué trois  stratégies  différentes  pour  le  traitement  de  la  resténose  intra-stent  :  angioplas-
tie avec  cutting  balloon, angioplastie  avec  ballon  au  paclitaxel  et  cutting  balloon  suivi  d’une
angioplastie  avec  ballon  au  paclitaxel.
Méthode.  —  Quarante-cinq  artères  coronaires  chez  45  cochons  ont  bénéﬁcié  d’une  angioplastie
par un  stent  métallique  surdimensionné  (ratio  stent/artère  :  2.1)  aﬁn  d’induire  une  resténose
intra-stent.  Après  28  jours,  une  resténose  intra-stent  déﬁnie  comme  un  diamètre  de  sténose
supérieur  ou  égal  à  50  %  de  l’artère  coronaire  ont  été  randomisés  dans  trois  groupes  :  angioplas-
tie avec  cutting  balloon, angioplastie  avec  ballon  au  paclitaxel  et  cutting  balloon  suivi  d’une
angioplastie  par  ballon  au  paclitaxel.  L’angiographie  in  vivo  a  été  réalisée  avant  l’intervention,
immédiatement  au  décours  et  à  28  jours.  Les  artères  stentées  ont  été  prélevées  pour  analyse
anatomopathologique.  La  prolifération  et  l’apoptose  des  cellules  musculaires  lisses  vasculaires
ont été  évaluées  par  immuno-histochimie  et  par  un  marquage  terminal  deoxynucléotidyle  trans-
ferase d’UTD  (marquage  TUNEL),  respectivement.
Résultats.  — La  réduction  immédiate  de  calibre  coronaire  n’était  pas  différente  dans  les  trois
groupes. La  réduction  tardive  du  diamètre  luminal  et  la  surface  néo-intimale  au  suivi  était
moindre dans  le  groupe  cutting  balloon  suivi  d’une  angioplastie  avec  ballon  au  paclitaxel,  com-
parativement  au  groupe  angioplastie  par  cutting  balloon  mais  similaire  au  groupe  angioplastie
par ballon  au  paclitaxel.  Il  n’y  avait  pas  de  différence  signiﬁcative  dans  la  détection  de  pro-
lifération de  cellules  musculaires  lisses  vasculaires  par  reconnaissance  antigénique  ou  par  le
test TUNEL,  entre  le  groupe  cutting  balloon  suivi  d’une  angioplastie  par  ballon  au  paclitaxel  et
le groupe  angioplastie  par  ballon  au  paclitaxel.
Conclusion.  —  L’angioplastie  par  ballon  au  paclitaxel  avec  ou  sans  cutting  balloon  s’avère
supérieure  à  l’angioplastie  par  cutting  balloon  seule  pour  la  prévention  de  la  resténose
intra-stent.  Le  mécanisme  est  probablement  lié  à  l’inhibition  de  la  prolifération  des  cellules
musculaires  lisses  vasculaires,  et  une  augmentation  de  l’apoptose.  Dans  ce  modèle  porcin  de
resténose coronaire,  l’angioplastie  par  ballon  au  paclitaxel  avec  ou  sans  cutting  balloon  s’avère
supérieure  aux  autres  méthodes  testées.
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reatment  of  in-stent  restenosis  (ISR)  remains  challenging.
everal  studies  have  shown  variable  results  using  bal-
oon  angioplasty  alone  [1],  repeat  stenting  [2—4], cutting
alloon  angioplasty  (CBA)  [5,6], intracoronary  irradiation
brachytherapy)  [7,8]  or  excimer  laser  angioplasty  [9].  Other
tudies  have  compared  these  different  techniques  and  it
s  still  unclear  which  one,  if  any,  will  provide  the  most
avourable  outcomes  [10—15].Recently,  paclitaxel-eluting  balloon  angioplasty  (PEBA)
as  been  developed  as  a  novel  approach,  which  combines
he  features  of  conventional  balloon  angioplasty  with  pacli-
axel  eluting  for  the  treatment  of  ISR.  Preclinical  trials  have
t
c
t
us  droits  réservés.
emonstrated  that  the  efﬁcacy  of  PEBA  in  the  treatment
f  ISR  is  superior  to  that  of  conventional  balloon  angio-
lasty  and  not  inferior  to  that  of  a  paclitaxel-eluting  stent
16,17].  However,  given  the  structure  of  the  paclitaxel-
luting  balloon,  it  must  have  some  of  the  shortcomings  of
onventional  balloon  angioplasty,  such  as  balloon  slippage
nd  edge  dissections  post  procedure.  All  these  shortcomings
ave  been  associated  with  cumbersome  procedures,  sub-
ptimal  results  and  adverse  clinical  and  angiographical
utcomes  [18]. The  use  of  CBA  could  potentially  reduce
he  occurrence  of  these  complications.  However,  the  out-
ome  of  cutting  balloon  predilatation  followed  by  PEBA  for
he  treatment  of  ISR  compared  with  PEBA  or  CBA  alone  is
nknown.
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The  aims  of  this  study  are  to  compare  28-day  imaging
and  pathology  outcomes  between  PEBA,  CBA  and  cutting
balloon  followed  by  paclitaxel-eluting  balloon  angioplasty
(CB  +  PEBA)  for  ISR  in  pig  models  and  to  elucidate  the  possi-
ble  mechanism.
Methods
All  animal  care  and  procedures  conformed  to  the  Guide  for
the  Care  and  Use  of  Laboratory  Animals  published  by  the
US  National  Institutes  of  Health  (NIH  Publication  No.  85-23,
revised  1996)  and  were  approved  by  the  Institutional  Animal
Care  and  Use  Committee  of  the  Second  Afﬁliated  Hospital  of
Harbin  Medical  University  (2009-X023).
Establishment of the in-stent restenosis model
Forty-ﬁve  mini-pigs  (20—25  kg)  were  pretreated  with  aspirin
(300  mg)  and  clopidogrel  (75  mg)  once  a  day  starting  3
days  prior  to  the  procedure.  Animals  were  intubated
after  sedation  with  ketamine  (20  mg/kg,  intramuscularly)
and  diazepam  (0.4  mg/kg,  intramuscularly),  followed  by
3%  sodium  pentobarbital  through  the  marginal  ear  vein
(25  mg/kg,  intravenously).  A  6-F  guiding  catheter  was  used.
Continuous  haemodynamic  and  surface  electrocardiographic
monitoring  was  maintained  throughout  the  procedure.  After
intravenous  heparin  (150  U/kg)  and  intracoronary  injection
of  nitroglycerin  (100  g),  baseline  angiography  of  the  target
vessel  was  performed.  The  methods  of  stent  implantation
have  been  published  previously  [19]. One  bare-metal  stent
(BMS)  (3.0—3.5  × 18  mm;  Lepu  Medical  Company,  Beijing,
China)  was  placed  at  12—14  atm  for  30  s  in  the  left  ante-
rior  descending  artery  of  each  pig.  The  stent-to-artery  ratio
was  maintained  at  1.2:1.  After  the  equipment  was  removed,
all  mini-pigs  were  sent  back  to  the  animal  house,  where  they
were  fed  a  normal  diet,  and  received  aspirin  (300  mg,  orally)
and  clopidogrel  (75  mg,  orally)  daily.
Interventional procedure for in-stent
restenosis
At  28  days  after  BMS  implantation,  a  repeat  angiography  was
performed.  The  segments  with  ISR  (≥  50%  diameter  steno-
sis)  by  quantitative  coronary  angiography  were  randomly
assigned  to  one  of  the  three  treatment  groups:  CBA,  PEBA
or  CB  +  PEBA.
Cutting balloon angioplasty
The  length  of  the  cutting  balloon  (Boston  Scientiﬁc,  Nat-
ick,  MA,  USA)  was  10—15  mm  and  the  diameter  was  chosen
according  to  the  size  of  the  stent  (cutting  balloon-to-stent
ratio,  1.1:1).  The  cutting  balloon  was  positioned  at  the
lesion  site  and  inﬂated  to  the  recommended  maximal  pres-
sure  of  10  atm  once.
Paclitaxel-eluting balloon angioplastyPredilation  of  the  target  lesion  was  usually  required  before
placement  of  the  study  device.  The  diameter  of  the  con-
ventional  non-study  balloon  catheter  was  0.5  mm  smaller
V
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han  that  of  the  paclitaxel-eluting  balloon.  The  paclitaxel-
luting  balloon  (3.0—3.5  ×  20  mm;  SeQuent  Please,  BRAUN,
ermany)  was  inﬂated  in  the  same  fashion  as  a  conventional
alloon  catheter  for  60  s  and  the  pressure  was  10  atm.
utting balloon followed by paclitaxel-eluting
alloon angioplasty
efore  the  paclitaxel-eluting  balloon  was  inﬂated,  predi-
ation  of  the  target  lesion  was  carried  out  with  a  cutting
alloon  catheter,  which  was  similar  in  diameter  to  a
aclitaxel-eluting  balloon.
uantitative coronary analyses
ngiograms  were  performed  during  the  initial  procedure,  on
ay  28  after  BMS  implantation  and  28  days  after  three  dif-
erent  strategies  for  the  treatment  of  ISR.  A  computerized
oronary  angiography  analysis  system  (GE  Company,  Ger-
any)  was  used  for  quantitative  coronary  analyses  by  two
xperienced  cardiologists  blinded  to  the  treatment  proto-
ol.  Discrepancies  were  resolved  by  mutual  consensus.  The
mmediate  lumen  diameter  (LD)  gain  (minimum  LD  imme-
iately  after  the  interventional  procedure  minus  minimum
D  before  the  interventional  procedure)  and  late  lumen  loss
minimum  LD  immediately  after  the  interventional  proce-
ure  minus  minimum  LD  at  follow-up)  were  calculated.
athological evaluation
or  the  morphometric  analysis,  stented  arteries  were  har-
ested  and  ﬁxed  in  10%  buffered  formalin  and  embedded
n  glycol  methacrylate.  Stented  segments  were  cut  into
hree  parts  (proximal,  mid  and  distal).  Thin  sections  from
ach  artery  block  were  stained  with  haematoxylin  and  eosin
nd  Verhoeff  van  Giesen  for  measurement  of  the  external
lastic  lamina  area  (EELA),  lumen  area  (LA)  and  internal
lastic  lamina  area  (IELA).  The  neointimal  area  (NA)  was
alculated  using  the  equation  NA  =  IELA  −  LA.  The  percent-
ge  of  lumen  area  stenosis  (AS%)  was  calculated  using  the
quation  AS%  =  (NA/IELA)  ×  100.  Injury  score  at  each  strut
ite  was  assessed  as  described  by  Schwartz  et  al.  [20],
here:  0  =  no  injury;  1  =  break  in  the  internal  elastic  mem-
rane;  2  =  perforation  of  the  media;  and  3  =  perforation  of
he  external  elastic  membrane  to  the  adventitia.  The  mean
njury  score  for  each  segment  was  calculated  by  dividing
he  sum  of  injury  scores  by  the  total  number  of  struts  at  the
xamined  section.
Stent  wires  were  carefully  removed  and  the  tissue
as  embedded  in  parafﬁn.  Vessel-wall  expression  of  pro-
iferating  cell  nuclear  antigen  (PCNA)  was  evaluated  by
mmunohistochemical  analyses  (Santa  Cruz  Biotechnology,
anta  Cruz,  CA,  USA).  Apoptosis  of  vascular  smooth  muscle
ells  (VSMCs)  was  evaluated  by  the  terminal  deoxynu-
leotidyl  transferase  dUTP  nick  end  labelling  (TUNEL)  assay.
here  were  three  cross-sections  of  each  arterial  specimen
o  analyse.  The  samples  were  incubated,  developed,  and
ounterstained  with  haematoxylin.  The  total  number  of
SMCs  in  each  randomly  chosen  neointimal  cross-section  was
easured  with  computer  assistance  at  ×  400  magniﬁcation
Pro  Plus  5.0  software).  The  percentages  of  proliferating  or
poptotic  VSMCs  were  obtained  by  dividing  the  number  of
82  J.  Kong  et  al.
Table  1  Quantitative  coronary  angiography  results.
Variables  CBA  PEBA  CB  +  PEBA  P
(n  =  11)  (n  =  10)  (n  =  10)
Baseline
Reference  diameter  (mm) 2.67 ± 0.24  2.52 ±  0.18  2.59 ±  0.25  0.8951
Stent  diameter  (mm)  3.21  ±  0.34  3.12  ±  0.22  3.18  ±  0.28  0.912
Balloon-to-artery  ratio  1.24  ±  0.06  1.25  ±  0.02  1.22  ±  0.08  0.6312
MLD  (mm)  1.01  ±  0.28  1.06  ±  0.23  1.05  ±  0.41  0.5413
Diameter  stenosis  (%)  60.2  ±  10.1  61.2  ±  7.5  63.7  ±  12.1  0.6338
Post  intervention
Reference  diameter  (mm)  2.65  ±  0.19  2.61  ±  0.22  2.65  ±  0.28  0.796
MLD  (mm) 2.15 ± 0.14  2.17  ±  0.13  2.19  ±  0.35  0.765
Acute  lumen  gain  (mm)  1.12  ±  0.36  1.12  ±  0.16  1.15  ±  0.41  0.785
Follow-up  at  28  days
Reference  diameter  (mm)  2.63  ±  0.15  2.61  ±  0.17  2.65  ±  0.20  0.8125
MLD  (mm) 1.25  ±  0.57  2.04  ±  0.14* 2.05  ±  0.38* 0.003
Late  lumen  loss  (mm) 0.89  ±  0.63  0.13  ±  0.04* 0.11  ±  0.05* 0.0406
Data are expressed as mean ± standard deviation. CBA: cutting balloon angioplasty; CB + PEBA: cutting balloon followed by paclitaxel-
eluting balloon angioplasty; MLD: minimal luminal diameter; PEBA: paclitaxel-eluting balloon angioplasty. Late lumen loss: post
intervention MLD — follow-up MLD. A P value < 0.05 indicates a signiﬁcant difference.
* P < 0.05 compared with CBA.
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SMCs  in  each  cross-section;  the  results  were  then  aver-
ged.
tatistical analyses
ata  are  expressed  as  means  ±  standard  deviations  except
here  noted.  The  mean  angiographical,  histological  and
orphological  data  for  each  stent  were  compared  by  one-
ay  analysis  of  variance  with  post  hoc  analysis  for  multiple
omparisons.  A  value  of  P  <  0.05  was  considered  signiﬁcant.
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igure 1. Morphometric analyses at follow-up (28 days) of three inte
taining (× 20) of cross-sections of coronary arteries treated with (A) cut
nd (C) cutting balloon followed by paclitaxel-eluting balloon angioplastll  statistics  were  calculated  with  SPSS  version  18.0  soft-
are.
esults
orty-ﬁve  mini-pigs  underwent  successful  implantation  of
5  BMSs  in  the  left  anterior  descending  artery.  All  mini-pigs
urvived  until  the  end  of  experiments.  Thirty-one  out  of  45
esions  (68.9%)  had  greater  or  equal  to  50%  diameter  steno-
is  and  the  mean  angiographical  stenosis  was  62.2  ±  10.3%.
rventional groups for in-stent restenosis. Haematoxylin and eosin
ting balloon angioplasty, (B) paclitaxel-eluting balloon angioplasty
y.
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Table  2  Histomorphometric  analysis  at  follow-up.
Variable  CBA  PEBA  CB  +  PEBA  P
(n  =  11) (n =  10) (n =  10)
LA  (mm2)  2.39  ±  0.77  5.15  ±  0.89* 5.34  ±  1.15* 0.0043
IELA  (mm2)  8.06 ±  0.92  8.12 ±  0.95  8.09 ±  1.62  0.8259
EELA  (mm2)  8.98 ±  0.87  9.10 ±  1.04  9.19 ±  0.91  0.8576
NA  (mm2)  5.68 ±  1.10  2.96 ±  0.67* 2.66 ±  0.69* 0.0202
AS%  63.36  ±  8.44  37.71  ±  6.31* 34.76  ±  5.83* 0.0015
Injury  score  1.39  ±  0.12  1.36  ±  0.14  1.37  ±  0.14  0.8741
Data are expressed as mean ± standard deviation. AS%: percentage of lumen area stenosis; CBA: cutting balloon angioplasty; CB + PEBA:
cutting balloon followed by paclitaxel-eluting balloon angioplasty; PEBA: paclitaxel-eluting balloon angioplasty; EELA: external elastic
lamina area; LA: lumen area; IELA: internal elastic lamina area; NA: neointimal area. A P value < 0.05 indicates a signiﬁcant difference.
*
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oP < 0.05 compared with CBA.
At  the  end  of  the  experiments,  there  were  11  lesions  in  the
CBA  group,  10  lesions  in  the  PEBA  group  and  10  lesions  in
CB  +  PEBA  group.
Angiographical ﬁndings
Quantitative  coronary  angiography  results  are  summarized
in  Table  1.  There  were  no  signiﬁcant  differences  in  baseline
and  immediate  angiographical  measurements  among  the
three  groups.  At  follow-up,  late  lumen  loss  in  the  CB  +  PEBA
group  was  signiﬁcantly  less  than  that  in  the  CBA  group,  but
similar  to  that  in  the  PEBA  group  (P  >  0.05).Histopathological analyses
The  histological  analysis  is  illustrated  in  Fig.  1.  There
were  no  differences  between  the  three  groups  in  injury
a
1
g
Figure 2. Immunohistochemical staining of vascular smooth muscle c
group: (A) cutting balloon angioplasty (CBA); (B) paclitaxel-eluting ballo
eluting balloon angioplasty (CB + PEBA) (× 400; bar 50 m).  (D) Percentacore.  LA  was  largest  (P  =  0.0043)  but  NA  and  AS%  were
mallest  (P  =  0.0202  and  P  =  0.0015,  respectively)  in  the
B  +  PEBA  group  (Table  2).  There  were  no  differences  in
A,  NA  and  AS%  between  the  PEBA  group  and  the  CB  +  PEBA
roup.
Immunohistochemical  staining  of  PCNA  is  shown  in  Fig.  2.
evels  of  protein  expression  of  PCNA  were  signiﬁcantly  lower
n  the  CB  +  PEBA  group  (16.2  ±  4.6%)  and  the  PEBA  group
16.1  ±  3.2%)  compared  with  the  CBA  group  (34.7  ±  7.8%,
 =  0.01978  and  P  =  0.0216,  respectively).  Quantiﬁcation  of
UNEL  staining  (Fig.  3)  in  the  intima  of  the  stented  arteries
howed  that  TUNEL-positive  cells  represented  38.1  ±  9.6%
f  the  total  number  of  VSMCs  in  the  CB  +  PEBA  group
nd  35.9  ±  6.9%  in  the  PEBA  group.  In  contrast,  only
6.2  ±  4.7%  of  VSMCs  were  TUNEL-positive  in  the  CBA
roup.
ells (VSMCs) for proliferating cell nuclear antigen (PNCA) in each
on angioplasty (PEBA); (C) cutting balloon followed by paclitaxel-
ge of PCNA-positive VSMCs; *P < 0.05 compared with CBA.
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Figure 3. Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) staining of each group: (A) cutting balloon angioplasty
(CBA); (B) paclitaxel-eluting balloon angioplasty (PEBA); (C) cutting balloon followed by paclitaxel-eluting balloon angioplasty (CB + PEBA).
Apoptotic cells are indicated by brown staining of the nucleus. Morphological changes include dense nuclear staining and shrunken cells.
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iscussion
he  present  study  showed  that,  in  a  porcine  coronary  artery
estenosis  model,  CB  +  PEBA  was  similar  to  PEBA  alone  for
revention  of  restenosis  at  28  days.  Furthermore,  both
B  +  PEBA  and  PEBA  were  better  than  CBA  alone.
Although  drug-eluting  stents  are  currently  considered  the
est  possible  care  in  the  treatment  of  ISR  [2,3], they  are
ssociated  with  delayed  and  incomplete  endothelialization
nd  an  increased  risk  of  stent  thrombosis  [21—23]. Treat-
ent  of  patients  with  ISR  remains  a  challenge  and  optimal
reatment  of  ISR  has  not  been  established.
Previous  studies  demonstrated  that  the  efﬁcacy  of  PEBA
n  the  treatment  of  ISR  was  similar  to  that  of  the  drug-
luting  stent  [16,17,24]. However,  it  also  had  some  of  the
hortcomings  of  conventional  balloon  angioplasty.  The  com-
ination  of  other  adjuvant  therapies  could  improve  the
fﬁcacy  and  reduce  adverse  events.
In  patients  with  ISR,  intravascular  ultrasound  studies  have
hown  that  CBA  most  probably  acts  by  ﬁrst  cutting  or  sco-
ing  the  neointimal  plaque,  thus  lessening  the  elastic  and
brotic  continuity  of  the  internal  ﬁbrous  layer  and  making
he  tissue  more  amenable  to  being  pushed  outward  though
he  stent  struts  [25,26].  Compared  with  conventional  angio-
lasty,  CBA  is  also  associated  with  a  decreased  incidence  of
he  ‘watermelon’  or  ‘soap-bar’  effect,  which  is  associated
ith  poorer  acute  and  long-term  angiographical  results  [19].
e  assumed  that  cutting  balloon  predilatation  followed  by
EBA  for  treatment  of  ISR  might  better  than  PEBA  alone.In  our  study,  cutting  balloon  adjunctive  to  PEBA  did  not
urther  reduce  late  luminal  loss  and  obtain  larger  LA,  com-
ared  with  PEBA.  There  are  some  possible  explanations  for
his  unexpected  outcome.  First,  in  this  animal  model  of  ISR,
u
c
e
l as swelling, membrane rupture and irregular staining of chromatin
muscle cells; *P < 0.05 compared with CBA.
he  preinjured  arteries  were  normal  non-atherosclerotic
essels  and  the  nature  of  their  in-stent  intimal  substrate
as  composed  principally  of  proliferating  VSMCs  and  extra-
ellular  matrix.  Whether  the  information  on  tissue  reaction
o  cutting  balloon  in  this  pig  model  can  be  applied  to  the
uch  more  complex  ISR  in  humans  is  uncertain.  Given  the
tructure  of  the  cutting  balloon,  severe  calciﬁed  and  ﬁbrosis
esions  might  beneﬁt  more.
ISR  is  caused  by  neointimal  hyperplasia,  which  involves
bnormal  growth  of  VSMCs.  Some  studies  have  found  that
poptosis  may  be  a  beneﬁcial  antiproliferative  component
or  the  treatment  of  ISR  [27,28].  Our  results  showed  that  in
he  PEBA  and  CB  +  PEBA  groups,  PCNA  expression  of  VSMCs
as  lower  and  the  percentage  of  TUNEL-positive  VSMCs
as  higher  than  in  the  CBA  group.  This  suggests  that  PEBA
ould  induce  imbalance  of  apoptosis  and  proliferation  of
SMCs.  Accelerating  cell  apoptosis  might  be  one  of  the  prin-
ipal  mechanisms  by  which  PEBA  or  CB  +  PEBA  prevent  VSMC
verproliferation  and  induce  late  in-stent  neointimal  regres-
ion.
tudy limitations
his  study  had  several  limitations,  including  the  small  sam-
le  size  and  the  inability  to  perform  histological  analysis
mmediately  after  intervention.  The  study  was  also  limited
o  observations  in  the  lesions  produced  in  healthy  vessels,
he  relevance  of  which  to  the  human  clinical  condition  is
ncertain.  The  observation  period  was  only  4  weeks;  this
overs  the  most  critical  time  with  respect  to  thrombotic
vents  and  healing,  but  it  remains  to  be  determined  for  how
ong  the  beneﬁcial  effect  will  be  maintained  in  animals.
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Conclusions
PEBA  with  or  without  cutting  balloon  was  superior  to  CBA  for
the  treatment  of  ISR  in  a  pig  model.  The  underlying  mecha-
nism  was  probably  related  to  inhibition  of  VSMC  proliferation
and  increased  apoptosis.  Treatment  of  ISR  might  not  require
a  second  stent  implantation  and  PEBA  or  CB  +  PEBA  seemed
to  be  better.
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